Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (171-180 of 322) with videos related to

Pageof 33
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older AdultsStephanie B Tsai, Joanna Rhodes, Hongtao Liu, et al.
Oncotarget|September 15, 2016
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLLShruti Sharma, Natalie Galanina, Ailin Guo, et al.
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Blood Advances|August 30, 2023
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaFarhad Ravandi, Asad Bashey, James Foran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2021
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22Hagop M Kantarjian, Wendy Stock, Ryan D Cassaday, et al.
Frontiers in Oncology|July 3, 2023
Therapy of childhood acute lymphoblastic leukemia in resource-poor geospacesMoisés M Gallardo-Pérez, Robert Peter Gale, Oscar A Reyes-Cisneros, et al.
Blood|August 14, 2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Bayard L Powell, Barry Moser, Wendy Stock, et al.
Blood Advances|July 19, 2022
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCTMisha C Tran, Yasmin Hasan, Amy Wang, et al.
Leukemia & Lymphoma|February 26, 2008
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis productsMelinda K Gordon, Dorie Sher, Theodore Karrison, et al.
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
Pageof 33

Showing results (171-180 of 322) with videos related to

Sort By:
Pageof 33
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older AdultsStephanie B Tsai, Joanna Rhodes, Hongtao Liu, et al.
Oncotarget|September 15, 2016
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLLShruti Sharma, Natalie Galanina, Ailin Guo, et al.
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Blood Advances|August 30, 2023
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaFarhad Ravandi, Asad Bashey, James Foran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2021
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22Hagop M Kantarjian, Wendy Stock, Ryan D Cassaday, et al.
Frontiers in Oncology|July 3, 2023
Therapy of childhood acute lymphoblastic leukemia in resource-poor geospacesMoisés M Gallardo-Pérez, Robert Peter Gale, Oscar A Reyes-Cisneros, et al.
Blood|August 14, 2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Bayard L Powell, Barry Moser, Wendy Stock, et al.
Blood Advances|July 19, 2022
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCTMisha C Tran, Yasmin Hasan, Amy Wang, et al.
Leukemia & Lymphoma|February 26, 2008
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis productsMelinda K Gordon, Dorie Sher, Theodore Karrison, et al.
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
Pageof 33